AI Article Synopsis
- Eighteen elderly patients (76 years or older) with small cell lung cancer were treated with carboplatin and etoposide, with 17 patients evaluated for treatment efficacy.
- Overall response rates were high, with 88% for those with limited disease and 67% for extensive disease, while median survival times were 219 days for limited disease and 158 days for extensive disease.
- Side effects included severe blood-related issues like leukopenia and neutropenia in a significant number of patients, and there was one treatment-related death due to pneumonitis.
Article Abstract
Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88% for LD patients and 67% for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41%, 76%, 24% and 6% of patients, respectively. There was one treatment-related death due to pneumonitis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!